


IMMUNOLOGY

Ivan Roitt Jonathan Brostoff David Male



IMMUNOLOGY

IVAN M. ROITT
MA DSc(Oxon) FRCPath FRS


Professor and Head of Department
of Immunology
The Middlesex Hospital Medical School
London W1

JONATHAN BROSTOFF
MA DM(Oxon) FRCP FRCPATH

Reader in Clinical Immunology
Department of Immunology
The Middlesex Hospital Medical School
London W1

DAVID K. MALE
MA PhD

Research Associate
Department of Immunology
The Middlesex Hospital Medical School
London W1



Y2001394

The C. V. Mosby Company · St Louis · Toronto

Gower Medical Publishing · London · New York · 1985

DISTRIBUTORS

USA and Mexico

The C. V. Mosby Company
11830 Westline Industrial Drive, St. Louis, MO 63146

Canada

The C. V. Mosby Company Ltd
120 Melford Drive, Toronto, Ontario M1B 2X5

Japan

Nankodo Company Limited.
42-6, Hongo 3-chome, Bunkyo, Tokyo 113

All other Countries

Churchill Livingstone
Medical Division of Longman Group Limited,
Robert Stevenson House, 1-3 Baxter's Place,
Leith Walk, Edinburgh EH1 3AF

© Copyright 1985 by Gower Medical Publishing Ltd.,
34-42 Cleveland Street, London W1P 5FB, England. All Rights
reserved. No part of this publication may be reproduced, stored in a
retrieval system or transmitted in any form or by any means or
otherwise without the prior permission of the copyright holders.

British Library Cataloguing in Publication Data
Roitt, Ivan M.

Immunology
I. Immunology
I. Title II. Brostoff, Jonathan
III. Male, David K.
574.2'9 QR181

ISBN 0-906923-35-2 (Gower)
0-443-029121 (Churchill Livingstone)

Library of Congress Cataloging in Publication Data

Roitt, Ivan Maurice
Immunology
Bibliography: p.
Includes index.
1. Immunology. I Brostoff, Jonathan.
II. Male, David K., 1954- . III. Title.
QR181.R58 1985 616.07'9 85-750

ISBN 0-906923-35-2

Printed in Hong Kong by Mandarin Offset International

Preface

We believe this to be a remarkably unusual book. We have attempted to present the subject primarily with appealing visual images, many of which are the distillation of much complicated scientific research. These illustrations are complemented specifically by individual captions, and more generally by a concise narrative text which links these images into an evolving conceptual thread. The book covers basic immunology and the fundamental principles relating to clinical immunology. The subject is covered in some depth and much attention is given to the underlying experimental studies. We hope that anyone interested in immunology, be they undergraduate, postgraduate or clinician, will find this an attractive but nonetheless thorough account, which they will find difficult to put down once they have opened it.

We would like to acknowledge the many immunologists and molecular biologists whose research findings have been included to explain particular immunological reactions, and to develop ideas on the function of the immune system. We greatly admire their work, and hope we will be forgiven for not mentioning all these scientists individually. In some cases, we have selected particular items, or simplified experiments to make points more readily understood. Readers who wish to grapple with the fine details of the experiments and hypotheses may locate the original papers by reference to review articles included as further reading at the end of each chapter.

IMR
JB
DKM

Acknowledgements

The editors gratefully acknowledge the following individuals for the major contribution they have made to their respective chapters:

Dr. Ross St.Clair Barnetson, Consultant Physician and Senior Lecturer, Department of Dermatology, The Royal Infirmary, Edinburgh. (*Hypersensitivity – Type IV*)

Dr. David Brown, Consultant Immunologist, Department of Clinical Immunology, Addenbrooke's Hospital, Cambridge. (*Complement*)

Dr. Anne Cooke, Wellcome Senior Lecturer, Department of Immunology, The Middlesex Hospital Medical School, London. (*Genetic Control of Immunity*)

Dr. Michael Crumpton, Deputy Director of Research, Imperial Cancer Research Fund Laboratories, London. (*Major Histocompatibility Complex*)

Dr. Marc Feldman, Senior Research Scientist, Department of Zoology, University College, London. (*The Antibody Response*)

Professor Carlo Grossi, Professor of Pathology, Department of Pathology, University of Alabama in Birmingham, Alabama. (*Cells Involved in the Immune Response; The Lymphoid System; Development of the Immune Response*)

Dr. Tony Hall, Department of Microbiology and Immunology, The Oregon Health Sciences University, Portland, Oregon. (*Hypersensitivity – Type I*)

Dr. Frank Hay, Reader in Immunology, Department of Immunology, Middlesex Hospital Medical School, London. (*Generation of Antibody Diversity; Hypersensitivity – Type III*)

Dr. John Horton, Reader in Immunology, Department of Zoology, University of Durham, Durham. (*Evolution of Immunity*)

Dr. James Howard, Director of Biochemical Research, The Wellcome Research Laboratories, Beckenham. (*Immunological Tolerance*)

Dr. Peter Lydyard, Honorary Senior Lecturer and Research Associate, Department of Immunology, The Middlesex Hospital Medical School, London. (*Cells Involved in the Immune Response; The Lymphoid System; Development of the Immune Response*)

Dr Kenneth McLennan, Lecturer in Histopathology, Bland Sutton Institute of Histopathology, Middlesex Hospital, London. (*The Lymphoid System; Development of the Immune Response*)

Dr. Michael Moore, Head of the Division of Immunology, Paterson Laboratories, Christie Hospital and Holt Radium Institute, Manchester. (*Immunity to Tumours*)

Dr. Michael Owen, Staff Scientist, Imperial Cancer Research Fund, University College, London. (*Major Histocompatibility Complex*)

Dr. Graham Rook, Department of Pathology, The Middlesex Hospital Medical School, London. (*Cell-Mediated Immunity; Immunity to Viruses, Bacteria and Fungi*)

Professor Michael Steward, Professor of Immunology, Department of Medical Microbiology, London School of Hygiene and Tropical Medicine, London (*Antigen-Antibody Reactions; Immunological Tests*)

Dr. Janice Taverne, Research Associate, Department of Immunology, The Middlesex Hospital Medical School, London (*Immunity to Protozoa and Worms*)

Dr. Roger Taylor, Reader in Immunology, Department of Pathology, University of Bristol, Bristol. (*Regulation of the Immune Response*)

Professor John Turk, Professor of Pathology, Department of Pathology, The Royal College of Surgeons, London. (*Hypersensitivity – Type IV*)

Dr. Malcolm Turner, Reader in Immunology, Department of Immunology, Institute of Child Health, London. (*Antibody Structure and Function*)

Dr. Kenneth Welsh, Head of Tissue Typing (South Eastern and South Western Regions), Tissue Typing Laboratory, Guy's Hospital, London. (*Transplantation and Rejection*)

Project Editor
Designer
Assistant designer

David Bennett
Celia Welcomme
Mary Ross

Line Artist (diagrams)
Line Artist (line drawings)
Index

Karen Cochrane
Jeremy Cort
Janine Ross

Preface	viii	ANTIBODY STRUCTURE	5.3
Acknowledgements	viii	THE GENETIC BASIS OF ANTIBODY HETEROGENEITY	5.6
		Isotypic Variation 5.6, Allotypic Variation 5.6,	
		Idiotypic Variation 5.6	
		ANTIBODY EFFECTOR FUNCTIONS	5.6
		STRUCTURE IN RELATION TO FUNCTION	5.7
		STRUCTURE IN RELATION TO ANTIGEN BINDING	5.8
<hr/>			
1 Adaptive and Innate Immunity			
<hr/>			
THE INNATE IMMUNE SYSTEM	1.1		
Phagocytes 1.2, NK Cells and Soluble Factors 1.2			
INFLAMMATION	1.3		
Chemotaxis 1.4, Phagocytosis 1.4			
ANTIBODY – A FLEXIBLE ADAPTOR	1.5		
ANTIGEN	1.6		
ADAPTIVE IMMUNITY AND CLONAL SELECTION	1.6		
INTEGRATED DEFENCE MECHANISMS	1.7		
VACCINATION	1.9		
IMMUNOPATHOLOGY	1.9		
<hr/>			
2 Cells Involved in the Immune Response			
<hr/>			
LYMPHOID CELLS	2.2		
Morphological Heterogeneity of Lymphocytes 2.2, T Cells 2.2,			
B Cells 2.4, Lymphocyte Proliferation and Maturation 2.5			
'NULL' OR 'THIRD POPULATION' CELLS	2.8		
MONONUCLEAR PHAGOCYTIC SYSTEM (MONOCYTES)	2.8		
The Reticuloendothelial System 2.8, Antigen-Presenting			
Cells 2.10			
THE POLYMORPHONUCLEAR GRANULOCYTES	2.12		
(POLYMORPHS)			
Neutrophils 2.12, Eosinophils 2.13, Basophils and			
Mast Cells 2.13, Platelets 2.14			
SUMMARY	2.15		
<hr/>			
3 The Lymphoid System			
<hr/>			
Primary and Secondary Lymphoid Tissue 3.1			
PRIMARY LYMPHOID ORGANS	3.1		
The Thymus 3.1, The Bursa of Fabricius and its			
Mammalian Equivalent 3.2			
SECONDARY LYMPHOID ORGANS	3.2		
The Spleen 3.3, Lymph Nodes and the Lymphatic system 3.4,			
Mucosal Associated Lymphoid Tissue (MALT) 3.7			
LYMPHOCYTE RECIRCULATION	3.8		
<hr/>			
4 Major Histocompatibility Complex			
<hr/>			
INHERITANCE OF MHC GENES	4.1		
Inbred Mouse Strains 4.1			
ARRANGEMENT OF MHC GENES	4.2		
CELLULAR DISTRIBUTION OF MHC ANTIGENS	4.3		
RECOMBINATION BETWEEN INBRED STRAINS	4.3		
STRUCTURAL VARIATION IN MHC ANTIGENS – PUBLIC AND	4.3		
PRIVATE SPECIFICITIES			
Tissue Typing 4.4			
CURRENTLY RECOGNIZED HLA SPECIFICITIES AND	4.5		
LINKAGE DISEQUILIBRIUM			
STRUCTURE OF THE MHC ANTIGENS	4.6		
FUNCTIONS OF THE MHC ANTIGENS	4.8		
<hr/>			
5 Antibody Structure and Function			
<hr/>			
THE FIVE IMMUNOGLOBULIN CLASSES	5.1		
ANTIBODY FUNCTION	5.1		
IMMUNOGLOBULIN CLASSES AND SUBCLASSES	5.2		
THE OCCURRENCE AND PHYSICOCHEMICAL PROPERTIES	5.2		
OF IMMUNOGLOBULINS			
<hr/>			
6 Antigen-Antibody Reactions			
<hr/>			
ANTIGEN-ANTIBODY BINDING	6.1		
ANTIBODY AFFINITY	6.2		
AFFINITY AND AVIDITY	6.2		
ANTIBODY SPECIFICITY	6.3		
THE PHYSIOLOGICAL SIGNIFICANCE OF HIGH AND	6.5		
LOW AFFINITY ANTIBODIES			
DETERMINATION OF AFFINITY AND AVIDITY	6.5		
ANTIBODY AFFINITY HETEROGENEITY	6.5		
<hr/>			
7 Complement			
<hr/>			
THE COMPLEMENT PROTEINS	7.2		
Proteins of the Classical Pathway 7.2, Proteins of the			
Alternative Pathway 7.2			
A PRIMITIVE COMPLEMENT SYSTEM	7.3		
COMPARISON OF THE CLASSICAL AND ALTERNATIVE	7.3		
PATHWAYS			
THE CLASSICAL COMPLEMENT PATHWAY	7.4		
Fixation of C1 by Immunoglobulin 7.4, Fixation and			
Activation of C4 and C2 by the C1qrs Complex 7.5,			
Action of the C4b2b Complex on C3 to form C4b2b3b 7.6,			
Action of C3b on C5 7.6			
C3b (C4b) COATINGS AND IMMUNEADHERENCE	7.6		
ANAPHYLATOXIN FORMATION	7.7		
BIOLOGICAL EFFECTS OF C3a	7.8		
BIOLOGICAL EFFECTS OF C5a	7.8		
ASSEMBLY OF THE C5-9 MEMBRANE ATTACK COMPLEX	7.8		
THE ALTERNATIVE PATHWAY	7.9		
BREAKDOWN OF C3b	7.10		
COBRA VENOM FACTOR (CVF) AND C3 NEPHRITIC	7.10		
FACTOR (C3 Nef)			
EFFECT OF C3-9 DEPLETION ON THE ADAPTIVE IMMUNE	7.11		
RESPONSE			
INHERITED COMPLEMENT DEFICIENCIES AND THEIR	7.11		
EFFECTS IN MAN			
INHIBITION OF C1 AND HEREDITARY ANGIOEDEMA	7.12		
COMPLEMENT AND THE MAJOR HISTOCOMPATIBILITY	7.13		
COMPLEX			
<hr/>			
8 The Antibody Response			
<hr/>			
PRIMARY AND SECONDARY ANTIBODY RESPONSES	8.1		
ASSAYING ANTIBODY FORMING CELLS (AFCs) –	8.1		
THE PLAQUE ASSAY			
HAPTENS AND CARRIERS	8.2		
T-DEPENDENT AND T-INDEPENDENT ANTIGENS	8.3		
AFFINITY MATURATION	8.4		
ANTIGEN PRESENTATION	8.5		
MECHANISMS OF CELL COOPERATION	8.6		
T CELL FACTORS	8.7		
ADJUVANTS	8.9		
<hr/>			
9 The Generation of Antibody Diversity			
<hr/>			
THEORIES OF ANTIBODY FORMATION	9.1		
IMMUNOGLOBULIN VARIABILITY	9.2		

LIGHT CHAIN GENE RECOMBINATION	9.3
HEAVY CHAIN GENE RECOMBINATION	9.5
RECOMBINATION SEQUENCES	9.5
ADDITIONAL DIVERSITY	9.6
Variable Recombination 9.6, Somatic Mutation 9.6	
HEAVY CHAIN CONSTANT REGION GENES	9.8
MEMBRANE AND SECRETED IMMUNOGLOBULIN	9.9
PRODUCTION OF IMMUNOGLOBULIN	9.11

10 Regulation of the Immune Response

THE REGULATORY EFFECT OF ANTIBODY	10.1
THE REGULATORY EFFECT OF IMMUNE COMPLEXES	10.2
IDIOTYPIC REGULATION	10.3
EVIDENCE THAT IDIOTYPIC INTERACTIONS ARE IMPORTANT IN IMMUNOREGULATION	10.4
REGULATION BY CELLULAR MECHANISMS – SUPPRESSOR T CELLS	10.8
CELLULAR CIRCUITS	10.9
FUNCTION OF THE MHC IN REGULATION	10.10
REGULATION OF THE MODE OF RESPONSE	10.10
NON-SPECIFIC REGULATION	10.10
SELF/NON-SELF DISCRIMINATION	10.11

11 Cell-mediated Immunity

RECOGNITION OF ANTIGEN BY T CELLS	11.1
MHC RESTRICTION	11.2
T CELL RECEPTORS FOR MHC GLYCOPEPTIDES	11.3
T CELL RECEPTORS FOR ANTIGEN	11.3
Gene Arrangement and Structure of the T Cell Receptor 11.4, Immunoglobulin Idiotypes 11.4	
ANTIGEN-PRESENTING CELLS	11.4
ACTIVATION OF T CELLS BY ANTIGEN-PRESENTING CELLS	11.4
CELL-MEDIATED CYTOTOXICITY	11.5
MHC RESTRICTED CYTOTOXIC T CELLS	11.5
NATURAL KILLER CELLS	11.6
The Identity of NK Cells 11.6, Relationship of NK Cells to K Cells and Cytotoxic T Cells 11.6, Mechanism of NK Cell-Mediated Lysis 11.6	
ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)	11.6
THE CENTRAL ROLE OF MACROPHAGES	11.7
Macrophage Activation by T Lymphocyte-Derived Mediators 11.8	
LYMPHOKINES	11.8
The Nature of Lymphokines and the Cells of Origin 11.8, The Complexity of Macrophage Activation 11.10	

12 Immunological Tolerance

PATHWAYS TO TOLERANCE	12.2
PATHWAYS TO B CELL TOLERANCE	12.2
Clonal Abortion 12.2, Clonal Exhaustion 12.2, Functional Deletion 12.3, Antibody Forming Cell (AFC) Blockade 12.3	
PATHWAYS TO T CELL TOLERANCE	12.3
T-suppressors 12.3	
GENERAL CHARACTERISTICS OF T CELL AND B CELL TOLERANCE	12.3
Induction Time 12.4, Antigen Dose 12.4, Antigen Persistence 12.4, Specificity 12.4, Duration 12.4	
INCOMPLETE TOLERANCE	12.5
Affinity and Isotype Maturation 12.5, Humoral and Cell-Mediated Responses 12.5, Determinants 12.5, Tissue Specificity 12.5	

MECHANISMS OF TOLERANCE INDUCTION	12.6
Antigen-Induced Tolerance 12.6, Tolerance Enhanced by Immunosuppressive Drugs 12.8, Antibody-Induced Tolerance 12.9	
SELF TOLERANCE	12.10
TOLERANCE IN AREAS OF POTENTIAL THERAPEUTIC APPLICATION	12.11

13 Genetic Control of Immunity

GENES CONTROLLING THE IMMUNE RESPONSE	13.1
MHC LINKED IMMUNE RESPONSE GENES	13.1
LEVEL OF ACTION OF IMMUNE RESPONSE GENES	13.3
Antigen Presentation and T/B Cooperation 13.3, Cytotoxic T Cells 13.4	
ANTIGEN RECOGNITION BY T CELLS AND B CELLS	13.6
Immune Response to HEL 13.6, Cross-Reactive Idiotypes 13.7	
NON-MHC IMMUNE RESPONSE GENES	13.8
GENETICALLY IMMUNODEFICIENT MOUSE STRAINS	13.8
B Cell Defects 13.8, Models of Autoimmune Disease 13.9	
DEVELOPMENT OF THE GENES OF THE IMMUNE SYSTEM	13.9

14 Development of the Immune System

LYMPHOID CELLS	14.1
T Cells 14.2, B Cells 14.4	
DEVELOPMENT OF CLASS DIVERSITY	14.5
DEVELOPMENT OF ANTIBODY DIVERSITY	14.6
DEVELOPMENT OF MONONUCLEAR PHAGOCYTES AND ANTIGEN-PRESENTING CELLS	14.7
THE COMPLEMENT SYSTEM	14.7
DEVELOPMENT OF NEUTROPHIL FUNCTIONS	14.7

15 Evolution of Immunity

INVERTEBRATE IMMUNITY	15.1
Immunocytes 15.1, 'Lymphoid' Tissues 15.2, Cell-Mediated Immunity 15.2, Non-Specific Defence 15.3	
VERTEBRATE IMMUNITY	15.4
T and B Functions 15.4	
MORPHOLOGY OF LYMPHOID TISSUES IN LOWER VERTEBRATES	15.5
Thymus 15.5, Spleen 15.6, Lymphomyeloid Nodes 15.6, Gut-Associated Lymphoid Tissue 15.7, Kidney 15.7, Bone Marrow 15.7	
ASPECTS OF AMPHIBIAN IMMUNOLOGY	15.8
Thymus Development: <i>Xenopus laevis</i> 15.8, Alloimmunity: <i>Rana pipiens</i> 15.9, Immunoglobulin Production 15.10, Metamorphosis and Immunoregulation 15.10, Models for the Study of Lymphocyte Development 15.10	

16 Immunity to Viruses, Bacteria and Fungi

IMMUNITY TO VIRUSES	16.1
Viral Infection 16.2, Effects of Antibody 16.3, Antibody Dependent Cell-Mediated Cytotoxicity 16.4, Cytotoxic T Cells and MHC Restriction 16.4, Delayed Hypersensitivity to Viral Antigens 16.5, Interferon 16.5, Immunopathology 16.6	
IMMUNITY TO BACTERIA	16.6
Bacterial Cell Walls 16.6, Adjuvantcity and Other Non-Specific Mechanisms 16.7, The Role of Antibody 16.8, Interaction with Phagocytes 16.9, The Killing Mechanisms of Polymorphs and Macrophages – Non-Oxygen-Dependent 16.9, Oxygen-Dependent Killing Mechanisms 16.10, Defence Mechanisms in Bacterial Infection 16.10	
IMMUNITY TO FUNGI	16.11

17 Immunity to Protozoa and Worms

GENERAL FEATURES OF PARASITIC INFECTIONS	17.1
EFFECTOR MECHANISMS	17.2
The T Cell Responses Important in the Control of Parasite Infections 17.2, Effector Functions of Antibodies 17.5, Non-Specific Effector Mechanisms 17.8	
ESCAPE MECHANISMS	17.8
IMMUNOPATHOLOGICAL CONSEQUENCES OF PARASITE INFECTIONS	17.12
EXAMPLES OF MAJOR HUMAN PARASITES	17.13

18 Immunity to Tumours

A ROLE FOR THE IMMUNE SYSTEM?	18.1
EXTENT OF POSSIBLE IMMUNE RESPONSES TO TUMOURS	18.1
CELL-MEDIATED IMMUNITY TO TUMOURS – T CELL RESPONSES	18.2
Detection of T Cell-Mediated Immunity 18.3	
NATURAL IMMUNITY	18.4
NK Cells 18.4, Macrophages 18.6	
<i>IN SITU</i> CELLULAR RESPONSES	18.7
B CELL RESPONSES	18.8
TUMOUR SPECIFIC ANTIGENS	18.8
Retrogenetic Antigens 18.8, Tumour Associated Transplantation Antigens 18.9	
IMMUNE COMPLEXES	18.10
IMMUNOSURVEILLANCE	18.11
IMMUNOLOGICAL ESCAPE	18.12
POTENTIAL FOR THERAPY	18.13

19 Hypersensitivity – Type I

TYPES OF HYPERSENSITIVITY	19.1
TYPE I – IMMEDIATE HYPERSENSITIVITY	19.2
Definition 19.2, Atopy 19.2	
IMMUNOGLOBULIN E	19.3
IgE Levels in Disease 19.4, Control of IgE Production 19.4	
GENETICS OF THE ALLERGIC RESPONSE	19.5
MAST CELLS	19.6
Distribution of Mast Cells 19.8, Difference Between MMCs and CTMCs 19.8, Other Fc ⁺ Receptor-bearing Cells 19.8, Mast Cell Triggering 19.9, T Cells and Mast Cell Triggering 19.10, Mediator Release 19.10	
CLINICAL TESTS FOR ALLERGY	19.12
THE CAUSES OF ALLERGY	19.14
T Cell Deficiency 19.14, Abnormal Mediator Feedback 19.15, Environmental Factors: The Concept of Allergic Breakthrough 19.16	
HYPOSENSITIZATION	19.16
THE BENEFICIAL ROLE OF IgE	19.17

20 Hypersensitivity – Type II

DAMAGE MECHANISMS	20.1
TRANSFUSION REACTIONS	20.4
HAEMOLYTIC DISEASE OF THE NEWBORN (HDNB)	20.5
AUTOIMMUNE HAEMOLYTIC ANAEMIAS	20.6
Warm-Reactive Autoantibodies 20.6, Cold-Reactive Autoantibodies 20.6	
DRUG INDUCED REACTIONS TO COMPONENTS OF BLOOD	20.6
REACTIONS TO LEUCOCYTES	20.7
HYPERACUTE GRAFT REJECTION	20.7
SENSITIVITY TO GLOMERULAR BASEMENT MEMBRANE	20.8
MYASTHENIA GRAVIS	20.8
SENSITIVITY TO TISSUE ANTIGENS	20.9

21 Hypersensitivity – Type III

TYPES OF IMMUNE COMPLEX DISEASE	21.1
INFLAMMATORY MECHANISMS IN TYPE III HYPERSENSITIVITY	21.2
EXPERIMENTAL MODELS OF IMMUNE COMPLEX DISEASE	21.2
Serum Sickness 21.3, Autoimmune Complex Disease 21.4, The Arthus Reaction 21.4	
WHY DO COMPLEXES PERSIST?	21.5
WHY DO COMPLEXES DEPOSIT IN TISSUE?	21.6
Increase in Vascular Permeability 21.6, Haemodynamic Processes 21.6, Antigen Tissue Binding 21.6, Size of Immune Complexes 21.8, Immunoglobulin Class 21.8	
COMPLEMENT SOLUBILIZATION OF IMMUNE COMPLEXES	21.8
DETECTION OF IMMUNE COMPLEXES	21.9

22 Hypersensitivity – Type IV

REACTIONS OF DELAYED HYPERSENSITIVITY	22.1
JONES-MOTE HYPERSENSITIVITY	22.1
CONTACT HYPERSENSITIVITY	22.2
TUBERCULIN-TYPE HYPERSENSITIVITY	22.3
GRANULOMATOUS HYPERSENSITIVITY	22.4
CELLULAR REACTIONS IN DELAYED HYPERSENSITIVITY	22.5
DISEASES MANIFESTING DELAYED HYPERSENSITIVITY	22.7
Leprosy 22.7, Tuberculosis 22.8, Sarcoidosis 22.9, Schistosomiasis 22.9	

23 Autoimmunity and Autoimmune Disease

THE SPECTRUM OF AUTOIMMUNE DISEASE	23.2
GENETICS	23.3
PATHOGENESIS	23.4
AETIOLOGY	23.8
DIAGNOSTIC AND PROGNOSTIC ASPECTS	23.10
TREATMENT	23.11
POSITIVE INDUCTION OF AUTOIMMUNITY	23.11

24 Transplantation and Rejection

GENETICS OF TRANSPLANTATION	24.1
HISTOCOMPATIBILITY GENES	24.2
THE ROLE OF T CELLS	24.3
ALLOGENEIC RECOGNITION	24.4
ANTIGEN PRESENTATION	24.4
EFFECTS OF ANTIBODY	24.5
GRAFT FACTORS AFFECTING REJECTION	24.6
CLINICAL TISSUE TRANSPLANTATION	24.7
IMMUNOSUPPRESSION	24.8
Antigen Non-Specific Immunosuppression 24.8, Antigen-Specific Immunosuppression 24.8	

25 Immunological Tests

ANTIGEN AND ANTIBODY	25.1
Precipitation Reaction in Gels 25.1, Haemagglutination and Complement Fixation 25.3, Direct and Indirect Immunofluorescence 25.4, Radioimmunoassay and Enzyme-linked Immunoabsorbent Assay 25.5, Pure Antibodies 25.7	
LYMPHOCYTE POPULATIONS	25.8
Glossary	
Index	

1 Adaptive and Innate Immunity

Our environment contains a large variety of infectious microbial agents – viruses, bacteria, fungi and parasites. Any of these can cause pathological damage and if they multiply unchecked will eventually kill their host. It is evident that the great majority of infections in normal individuals are of limited duration and leave very little permanent damage. This is due to the individual's immune system which combats infectious agents.

The immune system is divided into two functional divisions, namely the innate immune system and the adaptive immune system. Innate immunity acts as a first line of defence against infectious agents and most potential pathogens are checked before they establish an overt infection. If these first defences are breached the adaptive immune system is called upon. The adaptive system produces a specific reaction to each infectious agent which normally eradicates that agent. Furthermore, the adaptive immune system remembers that particular infectious agent and can prevent it causing disease later (Fig. 1.1). For example, diseases such as measles and diphtheria produce a life-long immunity following an infection.




Fig. 1.1 Adaptive and innate immunity. When an infectious agent enters the body it first encounters elements of the innate immune system. These may be sufficient to prevent disease but if not, a disease will result and the adaptive immune system is activated. The adaptive immune system produces recovery from the disease and a specific immunological memory is established so that following reinfection with the same agent no disease results; the individual has acquired immunity to the infectious agent.

The innate and adaptive immune systems consist of a variety of molecules and cells distributed throughout the body whose functions are described below (Fig. 1.2). The most important cells are the leucocytes or white blood cells which are described fully in 'Cells Involved in the Immune Response'. The leucocytes fall into two broad categories: 1) phagocytes, including neutrophil polymorphs, monocytes and macrophages, which form part

of the innate immune system; 2) lymphocytes, which mediate adaptive immunity. Cells of the immune system (lymphoid cells) are organized into organs as described in 'The Lymphoid System'.

	Innate Immune System	Adaptive Immune System
	resistance not improved by repeated infection	resistance improved by repeated infection
soluble factors	lysozyme, complement, acute phase proteins eg. CRP, interferon	antibody
cells	phagocytes natural killer (NK) cells	T lymphocytes

Fig. 1.2 The major elements of the innate and adaptive immune systems. There is considerable interaction between the two systems. Immunity due to soluble factors is sometimes referred to as humoral immunity.

THE INNATE IMMUNE SYSTEM

The exterior of the body presents an effective barrier to most organisms; in particular, most infectious agents cannot penetrate intact skin (Fig. 1.3).




Fig. 1.3 Exterior defenses. Most of the infectious agents which an individual encounters do not penetrate the body's surfaces, but are prevented from entering by a variety of biochemical and physical barriers. The body tolerates a number of commensal organisms which compete effectively with many potential pathogens.




Fig. 1.4 Action of lysozyme on the cell wall of *S. aureus*.

In the structure of *S. aureus* cell wall proteoglycan the backbone of N-acetylglucosamine (GlcNac) alternates with N-acetylmuramic acid (MurNac) crosslinked by amino acid side chains (yellow) and bridges of 5-glycine residues (orange). Lysozyme splits the molecule at the places indicated.

The importance of this barrier is made abundantly clear when an individual suffers serious burns. In this case prevention of infection via the damaged skin is a major concern. Most infections enter the body via the epithelial surface of the nasopharynx, gut, lungs and genito-urinary tract. A variety of physical and biochemical defences protect these areas from most infections. For example, lysozyme is an enzyme distributed widely in different secretions which is capable of splitting a bond found in the cell walls of many bacteria (Fig. 1.4).

Phagocytes

If an organism penetrates an epithelial surface it encounters phagocytic cells of the reticuloendothelial system. These cells are of several different types but they are all




Fig. 1.5 Phagocytes of the reticuloendothelial system.

Many organs contain phagocytic cells. Cells of the monocyte/macrophage series (listed left) are derived from blood monocytes which are manufactured in the bone marrow. Monocytes pass out of the blood vessel and become macrophages in the tissues. The other phagocytes listed are also derived from bone marrow stem cells.

derived from bone marrow stem cells. Their function is to engulf particles, including infectious agents, internalize them and destroy them. For this purpose they are strategically placed where they will encounter such particles; for example, the Kupffer cells of the liver line the sinusoids along which blood flows while the synovial A cells line the synovial cavity (Fig. 1.5). The blood phagocytes include the neutrophil polymorph and the blood monocyte (Fig. 1.6). Both of these cells can migrate out of the blood vessels into the tissues in response to a suitable stimulus but they differ in that the polymorph is a short-lived cell while the monocyte develops into a tissue macrophage.




Fig. 1.6 Phagocytes. Apart from the fixed cells of the reticuloendothelial system there are polymorphonuclear neutrophils (left) and blood monocytes (right), both derived from bone marrow stem cells. Courtesy of Dr. P. M. Lydyard.

NK Cells and Soluble Factors

Natural killer (NK) cells are leucocytes capable of recognizing cell surface changes on virally-infected cells. The NK cells bind to these target cells and can kill them. The NK cells are activated by interferons which are themselves components of the innate immune system (Fig. 1.7). Interferons are produced by virally-infected cells and sometimes also by lymphocytes. Apart from their action on NK cells, interferons induce a state of viral resistance in uninfected tissue cells. Interferons are produced very early in infection and are the first line of resistance against many viruses.

The serum concentration of a number of proteins increases rapidly during infection. These are referred to as acute phase proteins. The concentrations of these acute phase proteins can increase from 2 to 100-fold by comparison with their normal levels and they remain elevated throughout the infection. An example of this is C-reactive protein, so-called because of its ability to bind the C protein of pneumococci. C-reactive protein bound to bacteria promotes the binding of complement which facilitates their uptake by phagocytes; this process of protein coating to enhance phagocytosis is known as opsonization (Fig. 1.8). Complement is a group of about twenty serum proteins, rather like the blood clotting system, which interact with each other and with other components of the innate and adaptive immune systems. The complement system is spontaneously activated by the surface of a number of microorganisms by the so-called alternative complement pathway. Following activation some complement components can cause opsonization of the microorganisms for phagocytes while others attract phagocytes to the site of infection.




Fig. 1.7 Interferon and NK cells. When a cell becomes infected by virus, or transforms into a cancerous cell its surface molecules are altered. These alterations can sometimes be recognized by natural killer (NK) cells which engage the cell and kill it. Virally-infected cells produce interferons which can signal to neighbouring tissue cells and put them into a state capable of resisting viral replication, so preventing virus spread. Additionally, interferons can activate NK cells and enhance their cytotoxic action.




Fig. 1.8 Acute phase proteins. Acute phase proteins (here exemplified by C-reactive protein) are serum proteins which increase rapidly in concentration (up to 100 fold) following infection (graph). They are important in the innate immunity to infection. C-reactive protein (CRP) recognizes and binds, in a Ca^{++} dependent fashion, to molecular groups found on a wide variety of bacteria and fungi. In particular it binds the phosphorylcholine moiety of pneumococci. The CRP acts as an opsonin and also activates complement with all the associated sequelae.

A further group of complement components causes direct lysis of the cell membranes of bacteria by the 'lytic pathway' (Fig. 1.9). Although the various molecules of the innate immune system have been described separately, *in vivo* they act in concert. For example, the destruction of bacterial cell walls by lysozyme facilitates an attack on the cell membrane by the lytic pathway complement components. As will become evident later the complement system performs a number of functions in addition to its action in opsonization and lysis of microorganisms. These can be summarized as the control of inflammation.




Fig. 1.9 Complement functions. The complement system has an intrinsic ability to lyse the cell membranes of many bacterial species (1). Complement products released in this reaction attract phagocytes to the site of the reaction — chemotaxis (2). Once they arrive at the site of reaction other complement components coating the bacterial surface allow the phagocyte to recognize the bacteria and facilitate bacterial phagocytosis — opsonization (3). These are all functions of the innate immune system, although the reactions can also be triggered by the adaptive immune system.

INFLAMMATION

Inflammation is the body's reaction to an injury such as an invasion by an infectious agent. In just the same way as it is necessary to increase the blood supply to active muscles during exercise to provide glucose and oxygen so it is also necessary to direct elements of the immune system into sites of infection. Three major things occur during this response namely:

1. An increased blood supply to the infected area,
2. Increased capillary permeability caused by retraction of the endothelial cells. This permits larger molecules to traverse the endothelium than would ordinarily be capable of doing so and thus allows the soluble mediators of immunity to reach the site of infection,
3. Leucocytes, particularly neutrophil polymorphs and to a lesser extent macrophages, migrate out of the capillaries and into the surrounding tissue. Once in the tissue they migrate towards the site of infection by a process known as chemotaxis. These three events manifest themselves as inflammation.

Chemotaxis

Chemotaxis is the process by which phagocytes are attracted to sites of inflammation (Fig. 1.10). It can be demonstrated *in vitro* that phagocytes will actively migrate up a concentration gradient of certain (chemotactic) molecules. Particularly active is C5a, a fragment of one of the complement components. When purified C5a is applied to the base of an ulcer *in vivo* neutrophil polymorphs can be seen sticking to the endothelium of the nearby capillaries shortly afterwards. Initially this occurs on the side of the capillary nearest the point of application but as the C5a diffuses further the neutrophils stick to all




Fig. 1.10 Chemotaxis. At a site of inflammation tissue damage and complement activation by the infectious agent cause the release of chemotactic peptides (eg. C5a, a fragment of one of the complement components, which is one of the most important chemotactic peptides). These peptides diffuse to the adjoining capillaries causing passing phagocytes to adhere to the endothelium (pavementing). The phagocytes insert pseudopods between the endothelial cells and dissolve the basement membrane (diapedesis). They then pass out of the blood vessel and move up the concentration gradient of the chemotactic peptides towards the site of inflammation.




Fig. 1.11 Electron micrographs showing the three phases of diapedesis. The first micrograph shows a leucocyte adhering to the capillary endothelium (left) before it




Fig. 1.12 Scanning electron micrograph showing leucocytes adhering to the wall of a venule in inflamed tissue. × 16,000. Courtesy of Professor M. J. Karnovsky.

sides of the endothelium before traversing the endothelium, crossing the basement membrane and migrating up the gradient of the chemotactic molecule. Adherence and diapedesis of leucocytes is illustrated in figures 1.11 and 1.12. Both neutrophil polymorphs and macrophages are attracted by C5a but neutrophils are the predominant cell in sites of acute inflammation reflecting their numerical preponderance in the blood.

Phagocytosis

Once they have arrived at a site of inflammation the phagocytes have to recognize the infectious agent. They have receptors on their surface which allow them to attach non-specifically to a variety of microorganisms, but the attachment is greatly enhanced if the microorganism has been opsonized by the C3b component of complement. Complement activation at the site of infection causes C3b to be deposited on the infectious agent and since both neutrophils and macrophages have receptors which specifically bind to C3b this allows the phagocytes to recognize their targets (Fig. 1.13). The importance of complement opsonization can be seen in those very rare patients who are genetically deficient in complement component C3. These patients suffer from recurrent bacterial infections and septicaemia.




Fig. 1.13 Phagocytosis. Phagocytes arrive at a site of inflammation by chemotaxis. They may then attach to microorganisms via their non-specific cell surface receptors, or if the organism is opsonized with a fragment of the third complement component (C3b) through activation of the complement system, attachment will be through the cell surface receptors for C3b. If the membrane now becomes activated by the attached infectious agent, it is taken into a phagosome by pseudopods which extend around it. Once inside, lysosomes fuse with the phagosome forming a phagolysosome and the infectious agent is killed by a battery of microbicidal mechanisms. Undigested microbial products may be released to the outside.





Fig. 1.14 Electron micrographic study of phagocytosis. These two micrographs show human phagocytes engulfing latex particles. $\times 3000$ (left), $\times 4500$ (right). Courtesy of Professor C. H. W. Horne.

After attachment the phagocytes proceed to engulf the microorganism by extending pseudopods around it. These fuse and the microorganism is internalized in a phagosome (Fig. 1.14). Lysosomes fuse with the phagosome and destroy the trapped microorganism. The mechanisms involved are described more fully in 'Immunity to Viruses, Bacteria and Fungi' and 'Immunity to Protozoa and Worms'.

ANTIBODY — A FLEXIBLE ADAPTOR

Problems arise when the phagocytes are unable to recognize the infectious agent either because they lack a suitable receptor for it or because the microorganism does not activate complement and so cannot become attached to the phagocyte via the C3b receptor. Ideally, what is needed is a flexible adaptor that can attach at one end to the microorganism and at the other to the phagocyte. In answer to this requirement molecules known as antibodies have evolved and these are fully described in 'Antibody Structure and Function'. Antibodies are a class of molecules produced by B lymphocytes of the adaptive immune system which act as flexible adaptors between the infectious agents and phagocytes (Fig. 1.15).




Fig. 1.15 Antibody — a flexible adaptor. When a microorganism lacks the inherent ability to activate complement or phagocytes, the body provides a class of flexible adaptor molecules with a series of different shapes which can attach to the surface of different microbes. These flexible adaptor molecules are, of course, antibodies and the body can make several million different antibodies able to recognize a wide variety of infectious agents. Thus the antibody illustrated binds microbe 1, but not microbe 2, by its 'antigen binding portion' (Fab) while the 'Fc portion' (which may activate complement) binds to Fc receptors on host tissue cells, particularly phagocytes.





phagocyte	opsonin	binding
1 	—	±
2 	complement C3b	++
3 	antibody	+
4 	antibody and complement C3b	++++

Fig. 1.16 Opsonization. Phagocytes have some intrinsic ability to bind directly to bacteria and other microorganisms (1), but this is much enhanced if the bacteria have activated complement (C3b) so that they can bind the bacteria via their C3b receptor (2). Opsonization of organisms which do not activate complement well, if at all, is performed by antibody (Ab) which acts as a bridge to attach the microbe to the Fc receptor on the phagocyte (3). If both antibody and C3b opsonize, binding is greatly enhanced (4).

Any particular antibody molecule can only bind to one type of infectious agent, the other end of the molecule binds to the phagocyte via a receptor, the Fc receptor. Macrophages, neutrophils and all other cells of the reticuloendothelial system have Fc receptors. Since antibodies also cause the activation of complement by the so-called ‘classical pathway’ infectious agents will often have both antibody and C3b bound to their surface. In this case the phagocyte will recognize the agent via both its Fc receptors and its C3b receptors so that attachment and phagocytosis are greatly enhanced (Fig. 1.16).

It should be evident that antibodies are effectively bifunctional molecules. One part, which is extremely variable between different antibodies, is responsible for binding to the many different infectious agents the body may encounter while the second, constant portion binds to the Fc receptors of cells and also activates complement. In fact, antibodies act as adaptors not just for phagocytes but also for other cells and different antibodies can act as adaptors for different cell types.

ANTIGEN

Antibody molecules do not bind to the whole of an infectious agent. Each antibody molecule binds to one of many molecules on the microorganism’s surface. Molecules to which antibodies bind are called antigens (*anti-body generators*). Different antibodies will bind to different antigens since each antibody is specific for a

particular antigen. Indeed, a particular antigen specifically induces the production of the antibodies which can bind to it. The way in which a sufficient diversity of antibody molecules are generated able to recognize different antigens, is explained in the ‘Generation of Antibody Diversity’. Each antibody binds to a particular part of the antigen called an antigenic determinant or epitope. Note that the terms antigenic determinant and epitope are synonymous. A particular antigen can have several different epitopes or may have several identical epitopes (Fig. 1.17). In reality, the antibodies are specific for the epitopes rather than for the whole antigen molecule but since each antigen has its own particular set of epitopes which are not usually shared with other antigens the collection of antibodies in an antiserum are effectively specific for the antigen. The characteristics of antigen-antibody combination are discussed in ‘Antigen-Antibody Reactions’.




Fig. 1.17 Antigens. Foreign molecules which generate antibodies are called antigens. Antigen molecules each have a set of antigenic determinants also called epitopes. The epitopes on one antigen (Ag1) are usually different from those on another (Ag2). Some antigens (Ag3) have repeated epitopes. Epitopes are molecular shapes recognized by the antibodies and cells of the adaptive immune system. Each cell recognizes one epitope rather than the whole antigen. Even simple microorganisms have many different antigens.

ADAPTIVE IMMUNITY AND CLONAL SELECTION

The specificity of the adaptive immune system is based on the specificity of the antibodies and lymphocytes. It is found that each lymphocyte is only capable of recognizing one particular antigen. Since the immune system as a whole can specifically recognize many thousands of antigens this means that the lymphocytes recognizing any particular antigen are a very small proportion of the total. How then is an adequate response to an infectious agent generated? The answer is by clonal selection. Antigen binds to the small number of cells which can recognize it and induces them to proliferate so that they now constitute sufficient cells to mount an adequate immune response, that is the antigen selects the specific clones of antigen-binding cells (Fig. 1.18).




Fig. 1.18 Clonal selection. Each antibody-producing cell (B cell) is programmed to make just one antibody, which is placed on its surface as an antigen receptor. Each B cell has a different antigen binding specificity (1-n). Antigen binds to only those B cells with the appropriate surface receptor. These cells are stimulated to proliferate and mature into antibody-producing cells and the longer-lived, memory cells, all with the same antigen binding specificity (2).




Fig. 1.19 Summary of self/non-self discrimination. The immune system discriminates self from non-self, and reacts against non-self molecules (antigens). Following a primary contact with antigen, there are weak adaptive, and non-adaptive responses, but if the same antigen persists or is encountered a second time there is a much enhanced specific response to that antigen. The characteristics of an adaptive immune response are specificity and memory.

This process occurs both for the B lymphocytes, which proliferate and mature into antibody-producing cells and for the T lymphocytes, which are involved in the recognition and destruction of virally-infected cells.

This raises the question of exactly what the immune system is capable of recognizing. Broadly speaking, the immune system regards all molecules not belonging to the individual as 'non-self' and reacts against them, and it recognizes many of the individual's own molecules as 'self' but does not react against them. The failure to react to a potentially antigenic molecule is referred to as tolerance (see 'Immunological Tolerance'). The critical importance of self/non-self discrimination is outlined in figure 1.19 in the context of the adaptive and non-adaptive immune response. The body must both tolerate its own tissues and react effectively against all infective agents if disease is to be avoided.

INTEGRATED DEFENCE MECHANISMS

It will be appreciated that the innate and adaptive immune systems do not act in isolation. Antibodies produced by lymphocytes help phagocytes to recognize their targets. Following clonal activation by antigen, T lymphocytes produce lymphokines which stimulate phagocytes to destroy infectious agents more effectively. The macrophages in turn help the lymphocytes by transporting antigen from the periphery to lymph nodes and other lymphoid organs where it is presented to lymphocytes in a form they can recognize (Fig. 1.20).

The immune system is not the only system which protects the body from injury; the clotting, fibrinolytic and kinin systems are also involved in mediating inflammation and in the resolution of tissue damage. These systems interact to maintain the integrity of the vascular system and to limit the spread of tissue damage whether it is caused by physical damage or infectious agents.




Fig. 1.20 Interaction between lymphocytes and phagocytes. The adaptive and non-adaptive areas of the immune system interact at all levels. Lymphocytes are responsible for specific recognition: they produce antibody and lymphokines, soluble molecules which help the phagocytes combat the infection. Antigen processed by phagocytes and other cells which cannot themselves specifically recognize antigen, present the antigen to lymphocytes which can recognize it.




Fig. 1.21 The plasma enzyme systems in inflammation. This diagram summarizes the four plasma enzyme systems which interact in the control of inflammation. These are the clotting system (turquoise), the kinin system (light blue), the fibrinolytic system (pink) and the complement system (green). When tissue injury occurs enzymes are released and surfaces are exposed which activate Hageman factor XII and trigger mast cells to release histamine. Activated Hageman factor (XIIa) activates, and is reciprocally activated by, factor XIa and kallikrein. The kinin system produces bradykinin which induces pain, increased vascular permeability and vasodilation. Kallikrein activates the fibrinolytic system to produce plasmin which can activate Hageman factor and complement components and splits fibrin to produce chemotactic fibrinopeptides. Immunological events (for example, the combination of antibody with antigen) interact with these systems and modulate inflammation via the complement system. Different components (for example, C3a and C5a) trigger mast cells to release histamine producing vasodilation, increased capillary permeability and chemokinesis. (Other factors act as spasmogens, cause endothelial cell retraction, and are chemotactic for phagocytes.)

Immunological events can interact with this integrated system of damage control via the complement system (Fig. 1.21). Complement components released from sites of inflammation act directly on the local vasculature and the fragments C3a and C5a can also activate mast cells. These cells are widely distributed throughout the body and contain mediators which cause vasodilation and increased vascular permeability. The immune system can




Fig. 1.22 Immune system in acute inflammation. The adaptive immune system modulates inflammatory processes via the complement system. Antigen from microbes stimulates antigen-specific B cells to produce antibody; some (IgE) binds to mast cells while others (IgG and IgM) activate complement. Complement can also be activated directly by microbes via an alternative pathway. When triggered by microbial antigens the sensitized mast cell releases mediators. In association with complement (which also activates mast cells via C3a and C5a) the mediators induce local inflammation facilitating the arrival of phagocytes and more plasma enzyme system molecules.




Fig. 1.23 Innate and acquired mechanisms of killing intracellular organisms. Viruses and intracellular parasites stimulate T cells of the adaptive immune system (yellow). T-helper cells (T_H) cooperate in the maturation of T-cytotoxic cells (T_C) and release lymphokines, including interferon. T_C cells and NK cells can kill virally-infected cells. Interferons (also produced by the infected cell) stimulate NK cells and inhibit viral replication directly. Other lymphokines attract macrophages to the site of infection and enable them to kill intracellular organisms which would otherwise persist.

also interact directly with mast cells via a type of antibody (IgE) which binds to Fc receptors on the mast cell (Fig. 1.22). The inflammatory reaction effects the arrival of molecules and cells to the site of infection where they activate the macrophages to destroy their intracellular parasites (Fig. 1.23).

VACCINATION

Specificity and memory, two of the key elements of the adaptive immune response are exploited in vaccination since the adaptive immune system mounts a much stronger response on second encounter with antigen. The principle is to alter a microorganism or its toxins in such a way that they become innocuous without losing antigenicity. Take for example, vaccination against diphtheria. The diphtheria bacterium produces a toxin which is cytotoxic for muscle cells. The toxin can be chemically modified by formalin treatment so that it retains its antigenic epitopes but loses its toxicity; the resulting toxoid is used as a vaccine (Fig. 1.24). Other infectious agents such as polio can be attenuated so that they retain their antigens but lose their pathogenicity.




Fig. 1.24 Principle of vaccination. The principle of vaccination is illustrated by immunization with diphtheria toxoid. Diphtheria toxoid retains some of the epitopes of the diphtheria bacillus toxin so that a primary antibody response to these epitopes is produced following vaccination with toxoid. In a natural infection the toxin restimulates B memory cells which produce the faster and more intense secondary antibody response to the epitope so neutralizing the toxin.

IMMUNOPATHOLOGY

Up to this point the immune system has been presented as an unimpeachable asset. It is certainly true that deficiencies in any part of the immune system leave the individual exposed to a greater risk of infection, although other parts




Fig. 1.25 Undesirable consequences of immunity. Tissue damage may occur through the operation of immune mechanisms, either because the immune response is excessive or the antigen is persistent. Thus, in allergic patients, some innocuous antigen, such as pollen provokes an immune reaction out of proportion to any damage it might do; we speak of hypersensitivity reactions. The immune system recognizes foreign tissue grafts like any other antigen and rejects them. Sometimes the self/non-self recognition system breaks down and the body's own components are recognized as non-self (autoantigens) in which case autoimmune diseases can ensue.

of the system often partly compensate for such deficiencies. Clearly strong evolutionary pressures from infectious agents have led to the development of the system in its present form.

Nevertheless, there are occasions when the immune system is itself a cause of disease or other undesirable consequences (Fig. 1.25).

It has been stated that the immune system is established on a principle of self/non-self recognition. In some cases tolerance of self antigens breaks down and autoimmune disease may develop (see 'Autoimmunity and Autoimmune Disease'). In other cases innocuous antigens such as pollen are recognized and the immune system mounts an inappropriate response to them giving rise to symptoms of allergy. This is referred to as hypersensitivity and is discussed in 'Hypersensitivity Types 1, 2, 3, and 4'. Hypersensitivity reactions can also occur during infections. In some infections the amount of tissue damage produced by the immune reactions to a resistant microorganism may be comparable to that produced by the infection itself. It is often not possible to say where an advantageous reaction to an infection ends and hypersensitivity begins, particularly since the fundamental mechanisms underlying both are the same. In spite of these drawbacks it must always be remembered that overwhelming selective pressures have led to the development of the immune system as we see it today.

FURTHER READING

Golub E. S. (1981) *The Cellular Basis of the Immune Response*. Sinauer Associates, Massachusetts.

McConnell I., Munro A. & Waldmann H. (1981) *The Immune System: a Course on the Molecular and Cellular Basis of Immunity*, 2nd edn. Blackwell Scientific Publications, Oxford.

Nisonoff A. (1982) *Introduction to Molecular Immunology*. Sinauer Associates, Massachusetts.

Roitt I. M. R. (1984) *Essential Immunology*, 5th edn. Blackwell Scientific Publications, Oxford.

Sites D. P., Stubo J. D., Fudenberg H. H. & Wells J. V. (1984) *Basic and Clinical Immunology*, 5th edn. Lange Medical Publications, Los Altos, California.